MX374130B - Composiciones y metodos para reducir el contenido de alcohol en sangre. - Google Patents

Composiciones y metodos para reducir el contenido de alcohol en sangre.

Info

Publication number
MX374130B
MX374130B MX2015001553A MX2015001553A MX374130B MX 374130 B MX374130 B MX 374130B MX 2015001553 A MX2015001553 A MX 2015001553A MX 2015001553 A MX2015001553 A MX 2015001553A MX 374130 B MX374130 B MX 374130B
Authority
MX
Mexico
Prior art keywords
methods
alcohol content
compositions
blood alcohol
reducing blood
Prior art date
Application number
MX2015001553A
Other languages
English (en)
Other versions
MX2015001553A (es
Inventor
Johnathan Rinker
Kent Howard
Roxanne Smith
Original Assignee
Life Well Lived Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Well Lived Llc filed Critical Life Well Lived Llc
Publication of MX2015001553A publication Critical patent/MX2015001553A/es
Publication of MX374130B publication Critical patent/MX374130B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen composiciones y métodos para reducir el contenido de alcohol en sangre después del consumo de alcohol. Las composiciones y métodos de la invención rápidamente reducen el contenido de alcohol en sangre y mejoran síntomas de intoxicación en un sujeto que tiene un contenido elevado de alcohol en sangre debido al consumo de alcohol.
MX2015001553A 2012-08-03 2013-07-29 Composiciones y metodos para reducir el contenido de alcohol en sangre. MX374130B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261679308P 2012-08-03 2012-08-03
US201261691900P 2012-08-22 2012-08-22
US13/796,692 US9161957B2 (en) 2012-08-03 2013-03-12 Compositions and methods for reducing blood alcohol content
PCT/US2013/052500 WO2014022279A1 (en) 2012-08-03 2013-07-29 Compositions and methods for reducing blood alcohol content

Publications (2)

Publication Number Publication Date
MX2015001553A MX2015001553A (es) 2015-10-08
MX374130B true MX374130B (es) 2025-03-05

Family

ID=50028456

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015001553A MX374130B (es) 2012-08-03 2013-07-29 Composiciones y metodos para reducir el contenido de alcohol en sangre.
MX2020008031A MX2020008031A (es) 2012-08-03 2015-02-03 Composiciones y metodos para reducir el contenido de alcohol en sangre.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020008031A MX2020008031A (es) 2012-08-03 2015-02-03 Composiciones y metodos para reducir el contenido de alcohol en sangre.

Country Status (12)

Country Link
US (5) US9161957B2 (es)
EP (1) EP2879686B1 (es)
JP (1) JP2015525780A (es)
KR (1) KR102317376B1 (es)
CN (2) CN104640554A (es)
AU (1) AU2013296705B2 (es)
BR (1) BR112015002372A2 (es)
CA (1) CA2880841C (es)
EA (1) EA029407B1 (es)
MX (2) MX374130B (es)
WO (1) WO2014022279A1 (es)
ZA (1) ZA201501322B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456679A (zh) * 2013-05-10 2017-02-22 百通生物技术公司 包含含有片球菌和乳杆菌的细菌混合物的组合物和减小酒精影响的方法
NZ735777A (en) 2015-03-26 2023-03-31 Jacqueline M Iversen Methods and compositions to inhibit symptoms associated with veisalgia
NZ750188A (en) * 2017-06-09 2022-04-29 Sone Farm Co Ltd New lactic acid bacterium and use thereof
US10849938B2 (en) 2017-09-13 2020-12-01 ZBiotics Company Gene expression system for probiotic microorganisms
CN109350629B (zh) * 2018-08-09 2021-06-01 新乡医学院 一种用于治疗酒精戒断综合征的益生菌复合制剂及其制备方法
CN109567181A (zh) * 2018-10-15 2019-04-05 河南省锐达医药科技有限公司 一类食品原料组合物在解酒方面的应用
CN111297917A (zh) * 2019-12-23 2020-06-19 安徽新熙盟生物科技有限公司 一种缓解急性酒精中毒的益生菌制剂及制备方法和应用
US11723958B2 (en) * 2020-01-09 2023-08-15 SynLife, Inc. Microparticle-based enzyme systems for selective removal of target molecules
KR102262646B1 (ko) * 2020-04-02 2021-06-09 주식회사 메디뉴트롤 락토바실러스 플란타룸 v135 균주의 사균체를 유효성분으로 함유하는 숙취 예방 또는 해소용 조성물
KR102251295B1 (ko) * 2020-04-02 2021-05-12 주식회사 메디뉴트롤 락토바실러스 살리바리우스 v133 균주의 사균체를 유효성분으로 함유하는 숙취 예방 또는 해소용 조성물
US11344597B2 (en) 2020-07-21 2022-05-31 Purify Enterprises, LLC Compositions for reducing or preventing development of symptoms of alcohol consumption
US20220096515A1 (en) * 2020-09-28 2022-03-31 Huntington Medical Research Institutes Methods and Formulations for Preventing Neurological or Psychiatric Disorders
CN112458015B (zh) * 2020-11-27 2021-11-19 石家庄君乐宝乳业有限公司 长双歧杆菌长亚种i772、其分离纯化方法及应用
KR102390927B1 (ko) * 2021-07-22 2022-04-26 일동바이오사이언스(주) 락토바실러스 루테리 idcc 3701을 포함하는 숙취해소용 조성물
CN115919907A (zh) 2021-08-31 2023-04-07 E·施约林 一种用于治疗和/或预防食物和/或酒精中毒的组合物
US11458155B1 (en) 2021-11-16 2022-10-04 Fulgent Life Inc. Active ingredient complexes, compositions and methods for hangover relief and to ameliorate alcohol-induced liver damage
US20250195615A1 (en) * 2022-03-11 2025-06-19 The Board Of Regents Of The University Of Texas System Methods and compositions for the treatment of alcohol toxicity

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8521275D0 (en) 1985-08-27 1985-10-02 Blass D H Therapeutic composition
KR970008105B1 (ko) * 1993-06-28 1997-05-21 주식회사 미원 L-아스파테이트 또는 아스파라긴을 유효성분으로 함유하는 알콜성 장해 보호제 및 그의 제조방법
US5759539A (en) * 1995-06-06 1998-06-02 Georgia Research Foundation, Inc. Method for rapid enzymatic alcohol removal
KR0142615B1 (ko) 1995-09-16 1998-07-01 이은선 한국인 유아의 분변에서 분리해낸 내산성 및 콜레스테롤 분해능이 우수한 새로운 유산균 및 그 사용방법
AT411958B8 (de) * 1998-11-19 2004-09-27 Jhs Privatstiftung Erfrischungsgetränk zur steigerung der alkohol-abbau-kapazität
JP4465077B2 (ja) * 2000-02-15 2010-05-19 株式会社ヤクルト本社 アルコール吸収代謝調整剤
EP1227152A1 (en) 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium
CN1183839C (zh) * 2001-09-28 2005-01-12 陈廷伟 含脱氢酶解酒防醉保肝饮料
DE10218689A1 (de) 2002-04-26 2003-11-20 Degussa ADH aus Rhodococcus erythropolis
FI20021819A0 (fi) * 2002-10-14 2002-10-14 Pekka Untamo Heino Valmiste alkoholin metabolian tehostamiseksi
WO2005019438A1 (ja) 2003-08-21 2005-03-03 Otsuka Pharmaceutical Co., Ltd. 粘膜免疫賦活作用を有する乳酸菌
KR100543115B1 (ko) 2003-11-04 2006-01-20 주식회사한국야쿠르트 에탄올과 아세트알데하이드 분해효소 활성과 감소능이 우수한 젖산균
MXPA06009797A (es) * 2004-02-26 2007-08-14 Tasker Products Ip Holdings Co Composicion anti-microbiana para tratamiento pre-cosecha y post-cosecha de plantas y animales.
CN1968691B (zh) * 2004-04-19 2010-12-29 麒麟麦酒株式会社 用于通过葡糖异生作用加速酒精代谢或从疲劳恢复的组合物
US20050271739A1 (en) * 2004-06-08 2005-12-08 Wang Xiang H Methods and compositions for accelerating alcohol metabolism
KR100609779B1 (ko) 2004-11-29 2006-08-08 주식회사한국야쿠르트 알코올과 아세트알데하이드를 분해하는 젖산균
KR100661032B1 (ko) * 2005-04-19 2006-12-22 주식회사한국야쿠르트 간 기능 개선, 혈중 알코올 감소 및 항산화에 유효한조성물
US20060263385A1 (en) 2005-05-17 2006-11-23 Fran Gare Composition to relieve side effects of alcohol intoxication
US7956031B2 (en) 2005-05-31 2011-06-07 Naidu Lp Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy
PT1909600E (pt) * 2005-07-29 2012-07-24 Tima Foundation Composição para moderar o metabolismo do álcool e para reduzir o risco de doenças induzidas pelo álcool
US20100047320A1 (en) 2006-09-07 2010-02-25 Satya Prakash Oral polymeric membrane feruloyl esterase producing bacteria formulation
EP2324116B1 (en) 2008-08-01 2012-12-26 National Research Council of Canada Nucleotide sequence encoding an alcohol dehydrogenase from artemisia annua and uses thereof
CA2741942C (en) 2008-11-11 2018-01-16 Alimentary Health Limited Bifidobacterium longum strain bl1207
JP2009153529A (ja) * 2009-04-17 2009-07-16 Tsujido Chemical Corp 食品組成物
JP2010270101A (ja) * 2009-04-21 2010-12-02 Gekkeikan Sake Co Ltd アルコール吸収抑制組成物
US7888062B1 (en) 2010-02-01 2011-02-15 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
KR101271765B1 (ko) * 2010-06-17 2013-06-07 청송군 사과술 가미 막걸리 및 그 제조방법
EP2420147B1 (en) * 2010-08-17 2017-05-17 Vitae Natural Nutrition, S.L. Nutritional supplement compositon
US8440242B1 (en) * 2011-09-23 2013-05-14 Paul Grady Alcohol metabolizing assisting supplement

Also Published As

Publication number Publication date
EP2879686A1 (en) 2015-06-10
CA2880841C (en) 2022-11-08
KR102317376B1 (ko) 2021-10-25
US10918679B2 (en) 2021-02-16
CN104640554A (zh) 2015-05-20
CN114053312A (zh) 2022-02-18
KR20150041000A (ko) 2015-04-15
MX2020008031A (es) 2020-09-18
EP2879686A4 (en) 2015-11-25
US20170326185A1 (en) 2017-11-16
CA2880841A1 (en) 2014-02-06
EP2879686B1 (en) 2020-05-13
EA029407B1 (ru) 2018-03-30
US20140050702A1 (en) 2014-02-20
ZA201501322B (en) 2016-01-27
US11771724B2 (en) 2023-10-03
AU2013296705B2 (en) 2018-05-17
JP2015525780A (ja) 2015-09-07
WO2014022279A1 (en) 2014-02-06
MX2015001553A (es) 2015-10-08
US20210346440A1 (en) 2021-11-11
BR112015002372A2 (pt) 2017-07-04
US20160074445A1 (en) 2016-03-17
US9161957B2 (en) 2015-10-20
US20240245736A1 (en) 2024-07-25
EA201590301A1 (ru) 2015-10-30
AU2013296705A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
MX2020008031A (es) Composiciones y metodos para reducir el contenido de alcohol en sangre.
TWD158887S (zh) 粉餅盒
DK3195793T3 (da) Forbedringer i eller relateret til oftalmologi
TWD158794S (zh) 遮瑕膏容器
IN2014DN06104A (es)
BR112013023241A2 (pt) melhorias para entidades biológicas imobilizadas
UY34751A (es) ?composición de pienso para reducir la metanogénesis en rumiantes?
TWD159981S (zh) 化粧品容器
UY34822A (es) Composiciones y métodos para silenciar la expresión genética
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
CL2015001157A1 (es) Composiciones y métodos para tratar proteinopatías.
TWD169011S (zh) 自動點唱機之部分（三）
BR112015012907A2 (pt) composição de cuidado pessoal
UY34406A (es) Compuestos y métodos para mejorar la respuesta inmune innata
MX2015007033A (es) Nuevos derivados de piridina.
CO6850301A1 (es) Composiciones y métodos para mejorar la calidad del esperma procesado
IN2014DN03298A (es)
CO6930370A2 (es) Composiciones nutricionales de caseína-suero parcialmente hidrolizadas para reducir la aparición de alergias
EA201592085A1 (ru) Применение жирной кислоты таллового масла
DK2920282T3 (da) Alkylenkoblede phenoler til anvendelse i biodieselmotorer
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
EA201690856A1 (ru) Применение жирной кислоты таллового масла в связывании токсинов
EP2872605A4 (en) NOVEL FUEL COMPOSITION
EA201492280A1 (ru) Стабильный состав пексиганана
EA201492152A1 (ru) Налмефен для уменьшения потребления алкоголя у конкретных целевых популяций

Legal Events

Date Code Title Description
FG Grant or registration